Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia

…, C Desroches, X Du, R Gordon, J Guay…

文献索引：Oballa, Renata M.; Belair, Liette; Black, W. Cameron; Bleasby, Kelly; Chan, Chi Chung; Desroches, Carole; Du, Xiaobing; Gordon, Robert; Guay, Jocelyne; Guiral, Sebastien; Hafey, Michael J.; Hamelin, Emelie; Huang, Zheng; Kennedy, Brian; Lachance, Nicolas; Landry, France; Li, Chun Sing; Mancini, Joseph; Normandin, Denis; Pocai, Alessandro; Powell, David A.; Ramtohul, Yeeman K.; Skorey, Kathryn; Sorensen, Dan; Sturkenboom, Wayne; Styhler, Angela; Waddleton, Deena M.; Wang, Hao; Wong, Simon; Xu, Lijing; Zhang, Lei Journal of Medicinal Chemistry, 2011 , vol. 54, # 14 p. 5082 - 5096

全文：HTML全文

被引用次数: 60

摘要

The potential use of SCD inhibitors for the chronic treatment of diabetes and dyslipidemia has been limited by preclinical adverse events associated with inhibition of SCD in skin and eye tissues. To establish a therapeutic window, we embarked on designing liver-targeted SCD inhibitors by utilizing molecular recognition by liver-specific organic anion transporting polypeptides (OATPs). In doing so, we set out to target the SCD inhibitor to the organ ...